Press Releases
-
CD Genomics Introduces Advanced OxBS-seq Technology for Accurate Methylation Analysis
-
CD Genomics Unveils Groundbreaking Total RNA Sequencing and Dual RNA-seq Services
-
Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)
— Results Demonstrated that LYBALVI was Generally Well Tolerated With Stability of Body Weight and Metabolic Profile, and Durable Symptom Control, for Up to Four Years of Treatment —
Jan 3, 2024
-
Elligo Health Research Announces New CEO
John Potthoff Transitions to Chairman, Barry Simms Promoted to CEO
Jan 3, 2024
-
Mundipharma announces European approval of REZZAYO® (rezafungin) for the treatment of Invasive Candidiasis in adults
Mundipharma announces European approval of REZZAYO® (rezafungin) for the treatment of Invasive Candidiasis in adults. Approval based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive nonclinical development program.1,2 Rezafungin represents the first new treatment option in over 15 years for patients with invasive candidiasis.3
Jan 2, 2024
-
CD Formulation Extends Holiday Greetings for 2023 with an Exclusive Discount
-
Alfa Chemistry Launches Varieties of Biological Reagents for Use in Nucleic Acid Purification Systems
-
BOC Sciences and Spaya Join Forces to Expand Chemical Offerings
BOC Sciences, a leading chemical supplier, has partnered with Spaya, an AI-powered chemical synthesis platform, to enhance the portfolio of commercially available materials by listing an unprecedented 140,000+ chemical products.
Dec 20, 2023
-
Amerigo Scientific Highlights Cell-Free Expression Supplies with pEU Vector Set
-
Dr. Vince Clinical Research Launches New Solution for Organ Impairment Studies
-
Huateng Pharma Introduces Versatile Ingredients for Cosmetics and Commodities
Huateng Pharma introduces Tetrahydrocurcumin, a dual-action antioxidant and skin-whitening agent, alongside Pro-xylane and (S)-Pro-xylane, potent anti-ageing agents, and Piroctone Olamine, an effective anti-dandruff solution, emphasizing a commitment to quality and versatility from lab to commercial scale.
Dec 24, 2023
-
Andelyn Biosciences Selected by Ultragenyx for Late-Stage Process Performance Qualification (PPQ) Manufacturing of Novel Gene Therapy for Sanfilippo Syndrome
Columbus, OH, December 18, 2023 - Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), announced that it has been selected by Ultragenyx (NASDAQ: RARE) to perform late-stage Process Performance Qualification (PPQ) manufacturing of the company’s UX111 gene therapy for the potential treatment of Sanfilippo Syndrome (MPS IIIA).
Dec 19, 2023
-
Creative Biostructure Unveils Comprehensive Panel of Exosomes Isolated from Human Disease-State Body Fluids
-
Matexcel Provides Expansive Array of Bio-ink Products for Different Applications
-
Lifeasible Simplifies Gene Editing with CRISPR Mutation Library Construction Services
-
Creative Enzymes Unleashes Revolutionary Trypsin-Chymotrypsin, Elevating Protease Research to New Heights
-
Creative Enzymes Releases Microorganism-Derived Bilirubin Oxidase
-
Creative Proteomics Launches Innovative Ubiquitinated Proteomics Service for Advanced Research
-
Creative Proteomics Launches Label-free Quantification Service for Advanced Protein Analysis
-
Empower Your Research with Creative Proteomics' Innovative Pull-Down Assay Service